Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States
We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.
Authors
- Ellen Leschek (ORCID: https://orcid.org/0000-0002-2594-9955)
- Aaron Carlson (ORCID: https://orcid.org/0000-0001-7520-7864)
- Andrew B. Wolf (ORCID: https://orcid.org/0000-0002-1406-4107)
- Katie Glisic
- Antônio da Silva Ribeiro (ORCID: https://orcid.org/0000-0003-1888-1099)
- Elizabeth Matthews (ORCID: https://orcid.org/0000-0001-9823-9797)
- Joseph Y. Abrams (ORCID: https://orcid.org/0000-0002-2278-2467)
- Ryan A. Maddox
- Brian S. Appleby (ORCID: https://orcid.org/0000-0003-2275-3292)
- Lawrence B. Schonberger
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2025-05-28
- DOI
- https://doi.org/10.3201/eid3106.241519
- Citations
- 1
- Primary Topic
- Prion Diseases and Protein Misfolding
- Type
- article
- Field-Weighted Citation Impact
- 0.81